Equities research analysts expect that Biopharmx Corp (NYSE:BPMX) will announce $20,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Biopharmx Corp’s earnings, with estimates ranging from $10,000.00 to $30,000.00. Biopharmx Corp also posted sales of $20,000.00 during the same quarter last year. The business is scheduled to issue its next quarterly earnings results on Monday, September 11th.

According to Zacks, analysts expect that Biopharmx Corp will report full-year sales of $20,000.00 for the current financial year, with estimates ranging from $30,000.00 to $590,000.00. For the next fiscal year, analysts expect that the business will report sales of $5.07 million per share, with estimates ranging from $50,000.00 to $15.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Biopharmx Corp.

Separately, ValuEngine upgraded shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 24th.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/14/20000-00-in-sales-expected-for-biopharmx-corp-bpmx-this-quarter-updated.html.

Biopharmx Corp (NYSE:BPMX) opened at 0.30 on Thursday. The firm’s market capitalization is $22.24 million. The firm has a 50-day moving average of $0.44 and a 200 day moving average of $0.51. Biopharmx Corp has a 12-month low of $0.19 and a 12-month high of $1.22.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related stocks with our FREE daily email newsletter.